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The aim of this study was to examine the efficacy and toxicity of the epirubicin, carboplatin and 5-fluorouracil (ECarboF) regime in
patients aged 70 or less with metastatic prostate cancer resistant to LHRH analogues. The majority of patients had previously
received steroids as part of their systemic management and had progressive disease on steroids. In total, 80 patients were treated
over a 6-year period, with objective response rates (PSA or radiological) of 45% and median time to relapse of 9.5 months. Median
survival of the group was 9.2 months. In all, 32% of patients were alive at 12 months. Grade 3/4 neutropenia occurred in 34% of
patients with an 8.7% rate of neutropenic sepsis. Grade 3/4 nonhaematological toxicity occurred in 28% of patients. For a substantial
minority of patients with hormone refractory prostate cancer, combination chemotherapy can induce remission of significant
duration. While similar responses have been documented for systemic cytotoxic–steroid combinations, the responses in this study
are likely to reflect the activity of cytotoxic drugs alone.
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The value of cytotoxic chemotherapy in patients with metastatic
prostate cancer in progression following androgen suppression is
uncertain. In recent times, mitozantrone has been shown to
produce pain relief in a proportion of patients. In addition, using a
fall in plasma prostate-specific antigen (PSA) as an end point, an
additional 16–25% of patients (Berry et al, 2001; Kantoff et al,
2001) are seen to respond to the addition of mitozantrone to
steroid in randomised studies, compared to the use of steroids
alone (Tannock et al, 1996). A larger proportion of patients have
been shown to respond to combined drug treatments in phase 2
studies. However, these combinations often comprise cytotoxic
agents together with an oestrogen or a corticosteroid – the latter
often given as prophylaxis against nausea or against the allergic
manifestations of taxanes. Both oestrogens and corticosteroids
have antitumour effects in prostate cancer (Fossa et al, 2001), and
thus it is difficult to gauge the specific contribution of the cytotoxic
drugs. Combination chemotherapy with 5-fluoruracil, epirubicin
and cisplatin (ECF) in metastatic prostate cancer (Chao et al, 1997)
showed an encouraging response rate – over 40% – in a limited
number of patients. Carboplatin substitution for cisplatin (ECar-
boF) has been successfully implemented in the treatment of breast
cancer (Bonnefoi et al, 1996), and reduces auditory and renal
toxicity at the cost of additional myelotoxicity. We wished to
establish the efficacy and tolerability of this therapy in a large
group of patients with hormone-refractory metastatic prostate
cancer, while ensuring that any benefit related to the cytotoxic
agents rather than co-administered steroids.
MATERIALS AND METHODS
Eligibility
Patients with biopsy-proven adenocarcinoma of the prostate with
recurrent or metastatic disease, which had failed first-line
hormone therapy, were included in the study. Both symptomatic
and asymptomatic patients were eligible. Those without symptoms
had three successive rises in serum PSA, in keeping with the
American Society of Therapeutic Radiation Oncology guidelines
(Horwitz et al, 1998). Previous hormone therapy was continued,
with the exception of nonsteroidal antiandrogens (see below) and a
change of hormonal therapy was not permitted. All patients had a
PSA greater than 20ngml
 1, or bi-dimensionally measurable
disease. In general, only patients o70 years, with WHO
performance status 0–2, with no history of previous chemotherapy
were eligible. No previous hemi body radiotherapy or intravenous
strontium treatment was allowed. All patients were required to
have white blood cell (WBC) count 43.0 10
9l
 1 and platelets
4100 10
9l
 1. EDTA clearance was performed prior to commen-
cing chemotherapy. Serum alkaline phosphatase and renal
function was recorded prior to treatment and patients classified
into prognostic subgroups (Fossa et al, 1992).
Treatment
Patients received epirubicin 50mgm
 2 intravenously and carbo-
platin (calculated area under curve of 5) as an intravenous
infusion, both 4 weekly. Initially, protracted venous infusion (PVI)
5-Fluorouracil (5FU) at a dose of 200mgm
2day
 1 was given via a
Hickman line, but due to Hickman line difficulties, this was
changed mid-way through the study to 450mgm
 2 as a 1h
infusion on days 1 and 15 with folinic acid 20mgm
 2. All patients
with Hickman lines received low-dose anticoagulation, initially
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lwith 2mg daily of warfarin. If the patient was taking endocrine
therapy prior to chemotherapy, this was continued. If nonsteroidal
antiandrogen therapy had been recently discontinued, 8 weeks
were allowed to elapse before commencing chemotherapy to
exclude any response due to androgen withdrawal. Patients who
had responded to first-line hormonal therapy for o9 months were
usually given chemotherapy on relapse, whereas those patients
with longer response times were routinely given a trial of second-
line hormonal therapy, including oral hydrocortisone, before
chemotherapy was considered. Thus, the majority of patients had
disease which was also progressive on hydrocortisone therapy. In
these patients, dexamethasone as antiemetic prophylaxis was
given. Otherwise, steroids were omitted from the antiemetic
regime in view of their potential antitumour action. However, if
nausea persisted despite 5-HT3 antagonists, oral and/or intrave-
nous steroid therapy was considered. If there was a nadir platelet
count of o50 10
9l
 1 or pretreatment platelet count
o100 10
9l
 1, the carboplatin dose was reduced by 25%. If the
nadir WBC was WHO grade 3 (neutrophils o0.5 10
9l
 1), or
pretreatment WBC was WHO grade 2 (2.0–2.9 10
9l
 1), the
epirubicin dose was reduced by 25%.
Diarrhoea and stomatitis of WHO grade 2 or above resulted in a
20% reduction of 5FU, or temporary cessation of treatment for
those patients on PVI, followed by a 20% dose reduction. Six to
eight cycles of treatment were given. WHO grade of toxicity was
recorded at each cycle.
Response criteria
Patients were assessed prior to each cycle of chemotherapy for
symptomatic response or progression as described in the EORTC
Phase III 30853 study of hormonal therapy in metastatic prostate
cancer (Denis et al, 1993). Symptoms of progressive disease were
defined as a progression of urological symptoms with the
appearance of severe symptoms requiring surgical relief or
catheterisation, weight loss of more than 10% within 1 year, or
deterioration of WHO performance status. An increase in pain
score as reflected by a step up in the WHO analgesia classification
and ladder (Ventafridda et al, 1985) was also considered to reflect
progression. However, objective measures of symptom scores such
as Quality of Life tools and formal pain scores were not performed.
Serum PSA levels were measured prior to each cycle. Commonly
the PSA rose after chemotherapy commenced, prior to its falling
and in some cases, a fall in PSA was seen as a late event. The
overall PSA response to treatment was defined as a fall in the PSA
levels to less than 50% of pretreatment values, maintained for at
least 1 month after completion of six cycles of chemotherapy
(‘study criteria’), a definition used in our previous study of ECF
chemotherapy in the same patient group (Chao et al, 1997). PSA
response was additionally defined using the PSA international
consensus, as PSA level falling to less than 50% of pretreatment
values and sustained for at least one further reading 4 weeks later
(Bubley et al, 1999b). For measurable disease, complete response
was defined as the complete resolution of disease sites and partial
response as 450% reduction in the measurable lesions (measured
in two directions) sustained for 1 month after completion.
Progressive disease was defined as 425% increase in the size of
measurable lesions or the appearance of new lesions. Stable disease
was defined using the WHO definition of a less than 50% decrease
in total tumour size and o25% increase in the size of the
measurable lesions. Chemotherapy was discontinued if there was
clinical or radiological deterioration by week 8. Otherwise, three
cycles of chemotherapy were given before concluding that no
response had been achieved. The decision to continue or stop
chemotherapy was invariably made on the basis of patients’
clinical progress, assisted by PSA values and occasionally
radiological assessment. A rising PSA was based on a minimum
of two successive increases. If chemotherapy appeared to be
preventing progression, chemotherapy could be continued despite
a stable PSA. Treatment was also stopped if there was patient
intolerance or if six to eight cycles had been reached. If any
steroid-naı ¨ve patient had been commenced on steroids because of
vomiting or suspected spinal cord or nerve root compression, the
response documented at the cycle immediately prior to starting
steroids was used. This allowed an assessment of the response due
to cytotoxic therapy alone to be recorded. Duration of response
and survival were defined from the time chemotherapy was
initiated.
Sample size
The above regime is in regular use in our hospital. This report is
generated at a time when the number of patients treated gives a
lower confidence limit for response of greater than 25%.
RESULTS
Patient demographics (Table 1)
Between December 1995 and March 2002, 80 patients were entered,
73 of whom had elevated PSA levels (greater than 20ngml
 1) prior
to treatment. In all seven patients with nonelevated PSA, disease
was measurable on liver ultrasound and/or chest CT. The median
age was 64 years (range 48–72 years) with four patients above the
upper age limit, all of whom were of performance status 0–1 and
hence entered at the physician’s discretion. Patients were classified
into prognostic groups according to the Fossa classification (Fossa
et al, 1992), wherein duration of hormone response, performance
status, serum creatinine and alkaline phosphatase are predictive of
survival. Subgroups 1 2 and 3 were defined, with predicted
prognoses of 10, 6 and 3 months respectively. The majority of
patients selected for this study were thus in relatively good
prognostic categories. In total, 63 out of 80 patients (78%) had
symptoms of progressive disease as previously described. Patients
received a median of five cycles (range 1–8 cycles) and dose
reductions or delays were seen in 46 patients (57%). A total of 59
out of 80 patients (73%) had disease that was progressive on
hydrocortisone therapy, with a further 21 patients who had not
Table 1 Patient demographics
Number of patients 80
Age (years)
Median 64
Range 48–72
ECOG performance status
04 3
13 9
28
Symptomatic 63 (78%)
Asymptomatic 17
Site of disease
Bone only 56
Bone+soft tissue 20
Local recurrence only 4
Prostate-specific antigen on entry (ngml
 1) 196
Range 4.7–1832
Prognostic groups at entry
a
Group 1 24
Group 2 49
Group 3 7
aPrognostic subgroups according to Fossa et al (1992).
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lreceived steroids as antitumour systemic therapy. Seven of these 21
steroid-naive patients received dexamethasone during the study
due to persistent vomiting (five patients) or neurological
deterioration (two patients).
Toxicity
A total of 75 patients (93%) were evaluable for toxicity (Table 2).
The rate of neutropenic sepsis was low (8.7%) with nonhaemato-
logical WHO Grade 3 or 4 toxicity occurring in 22 patients
(27.5%). One patient developed left ventricular failure (New York
Heart Classification Grade 4) shortly after completing the sixth
cycle of chemotherapy, but his cardiac function subsequently
improved. There was one deep vein thrombosis despite prophy-
lactic low-dose warfarin anticoagulation, and one patient suffered
a subdural haematoma, the aetiology of which may have been
related to his anticoagulation or to an unrelated intracranial
haemorrhage. One patient also experienced rectal bleeding which
required discontinuation of chemotherapy.
Tumour response (Table 3)
In all, 36 out of the 80 (45%) patients responded by PSA (study
criteria) and/or radiological criteria (95% confidence interval (CI)
29–60%) with a median time to first suppression of PSA of 7 weeks
(range 3–14 weeks) from commencing chemotherapy. When the
specific study criteria of PSA response, defined as the fall in PSA
maintained for 1-month postcompletion of chemotherapy was
used, responses were seen in 30 out of 73 (41%) patients. When
PSA response as defined by International Criteria was used, PSA
responses were seen in 42 of the 73 (57%) patients with an elevated
PSA prior to treatment. In all, 12 patients did not maintain the fall
in PSA after completion of treatment. A slowing of the rate of rise
of serum PSA accompanied by a symptomatic response as
previously described was seen in a further five patients. Sympto-
matic response was seen in 41 out of 63 (65%) of patients who had
been symptomatic prior to starting treatment. Of the seven
patients with a pretreatment PSA of o20ngml
 1, radiological
responses, two of which were complete responses, were seen in six
patients. The median duration of response was 9.5 months (range
7–17 months). Median survival was 9.2 months (range 1–29
months). In total, 40% of patients were alive at 12 months and 11%
at 24 months.
DISCUSSION
Chemotherapy in prostate cancer has been traditionally dis-
counted, after disappointing results in the 1980s. Indeed, the
combination of mitozantrone and prednisolone (Berry et al, 2002)
although showing improvement in symptoms showed no survival
benefit. This finding was reflected in previous trials of chemother-
apy in prostate cancer comparing chemotherapy with best
supportive care alone. Poor response rates of 10–15% to single
agents with a median duration of response of 6–9 months have
been quoted (Brausi et al, 1995). However, early studies in the pre-
PSA era often relied on acid phosphatase levels and patient
symptoms as markers of response, as only 20% of patients with
metastatic prostate cancer, have measurable soft tissue disease
(Figg et al, 1996). Post-therapy PSA levels have become widely
accepted as a surrogate end point in the evaluation of treatment
Table 2 Grade 3/4 Haematological and nonhaematological toxicities in
75 evaluable patients
Haemoglobin 13 (16%)
Neutrophils 27 (33.8%)
Platelets 13 (16%)
Neutropenic sepsis 7 (8.7%)
Hickman line thrombus/re-insertion/shoulder pain 7/45 (15%)
Renal 1
Skin 2
Emesis 8 (of which five
were in steroid-
naı ¨ve group)
Diarrhoea 2
Stomatitis 4
Infection 2
Cardiac 1
Haematuria 2
Table 3 Response to EcarboF chemotherapy (80 patients evaluable)
PSA response
Defined per International criteria
a 42/73 (57%)
Defined per study criteria
b 30/73 (41%)
Radiological response
c 6/7
Total objective responses
Using International PSA response criteria 48/80 (60%)
Using study PSA response criteria 36/80 (45%)
Symptomatic response (doctor’s assessment) 41/63
d
aDefined as 450% fall in initial level maintained for at least 4 weeks.
bDefined as
450% fall in initial level maintained for at least 4 weeks from completion of
chemotherapy.
cPSA not elevated prior to treatment.
dIn the 63 patients who were
symptomatic at the initiation of treatment.
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Figure 1 (A) PSA trend in response to chemotherapy and addition of
steroids in Patient 1. 1–7: chemotherapy cycles; Dex: dexamethasone
commenced for a period of 6 weeks; ST; stilboestrol; HC: hydrocortico-
sone. (B) PSA trend in response to chemotherapy and subsequent
radiotherapy and steroids in Patient 2. 1–5: chemotherapy cycles;
DexþRT: dexamethasone and radiotherapy commenced; *dexametha-
sone given as antiemetic.
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lresponses in hormone-refractory prostate cancer (Smith et al,
1998). One suggestion is that a decline of 50% or greater from
baseline sustained over 2 months reflects a response (Kelly et al,
1993). We have used the Prostate Specific Antigen Working Group
(Bubley et al, 1999a) criteria of a greater than 50% fall in serum
PSA from pretreatment levels, sustained for at least 4 weeks but
also our own specific definition of the PSA fall being maintained
for a month or greater after completion of six cycles of
chemotherapy. Previous work from this institution has shown
response rates of 40% using epirubicin, cisplatin and 5-flurouracil
(Chao et al, 1997). However, significant toxicity is encountered
with ECF, particularly nausea, renal toxicity, peripheral neuro-
pathy and ototoxicity (Ross et al, 2002). Carboplatin substitution
for cisplatin minimises renal, auditory and neurological toxicity
and simplifies the out patient regime but may prove more
myelotoxic. It has not been used previously in metastatic
prostatic tumours. In other Phase II studies, the combination of
estramustine and docetaxel (Petrylak, 2002) has PSA response
rates of up to 74 with a 77% 1-year survival. However, neutropenia
rates were significant (43%) and prednisolone was also given
at high dose as part of the premedication regime with each cycle.
It is not clear, therefore, the extent to which docetaxel contri-
butes to the high response rate in the steroid–cytotoxic
combination.
We have previously presented data on the first 34 patients
treated with the ECarboF regime (Newby et al, 1999). The response
rate of ECarboF is similar (45 vs 43%) to that seen in a study from
this institution with ECF (Chao et al, 1997). In this previous study,
there was a 19% rate of Hickman line thrombosis, which has been
reduced to 6% (three out of 45 patients) by low-dose warfarin
anticoagulation. Other Hickman line problems including shoulder
pain and lines becoming dislodged occurred in four patients.
These problems lead to the discontinuation of 5-FU as a PVI and
the use of the 1h infusion of 5-FU on days 1 and 15. Previous
endocrine therapy was continued to ensure that any tumour clone
that was still hormone responsive did not relapse. Unlike other
current regimes where high response rates have been seen, a
change in hormonal management in addition to chemotherapy was
not permitted, and thus this study reflects the response to
chemotherapy alone. In those patients where clinical symptoms
necessitated commencement of steroids, assessment of tumour
response was documented prior to starting dexamethasone.
Although some authors have documented no extra antitumour
benefit from dexamethasone at high doses in combination with
taxane and estramustine containing chemotherapy regimes
(Weitzman et al, 2000), the antitumour effect of steroids alone
has been well documented, giving better subjective responses in
terms of improvements in pain score and performance status, and
similar PSA responses to antiandrogen therapy (Fossa et al, 2001).
The beneficial but confounding effects of steroids on tumour
response have been demonstrated in two steroid-naı ¨ve patients
treated in our institution with ECarboF subsequent to the current
series (Figure 1A and B). The administration of dexamethasone for
spinal cord compression in these two patients was followed by a
prompt fall in PSA, which may not have been seen with
chemotherapy alone.
This study confirms the efficacy and manageable toxicity of the
ECarboF regime in selected patients with hormone refractory
prostate cancer receiving treatment as outpatients. The number of
dose reductions and treatment delays illustrate that this is an
aggressive regime. It would, therefore, not be suitable for the
majority of patients, but should be considered for the sizeable
minority in whom combination chemotherapy is appropriate. The
encouraging response rate from ECarboF implies that combination
chemotherapy is superior to single-agent cytotoxic treatments.
This conclusion would require a randomised study, however,
where factors such as quality of life and overall survival would
additionally need to be compared.
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